6/9/2021 8:13:50 AM
PTC Therapeutics Elects Mary Smith To Board
5/26/2021 8:11:13 AM
PTC Therapeutics: FDA And EC Grant Orphan Drug Designation For PTC923 For Patients With Hyperphenylalaninemia
5/17/2021 9:38:09 AM
PTC Therapeuti : New Data Shows Devastating Impact Of AADC Deficiency On Caregivers
3/30/2021 1:02:11 AM
PTC Therapeutics: European Commission Grants Marketing Authorization To Evrysdi For Spinal Muscular Atrophy
3/9/2021 8:11:17 AM
SMA Foundation And PTC Expand Partnership To Advance Drug Discovery And Development Research In Regenerative Medicine
2/26/2021 6:57:44 AM
CHMP Adopts Positive Opinion For Evrysdi For Spinal Muscular Atrophy In Adults And Children Aged Two Months And Older
2/17/2021 8:28:34 AM
PTC Therapeutics Initiates Second Stage Of FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 For COVID-19
3/7/2018 6:54:56 AM
RBC Capital Markets Is Cutting PTC Therapeutics Inc. (PTCT) FY18 Estimate To -0.82 From -0.79
3/7/2018 6:54:39 AM
RBC Capital Markets Is Lowering PTC Therapeutics Inc. (PTCT) Q3 18 Estimate To -0.17 From -0.15
3/7/2018 6:54:21 AM
RBC Capital Markets Is Cutting PTC Therapeutics Inc. (PTCT) Q2 18 Estimate To -0.25 From -0.24
3/7/2018 6:54:06 AM
RBC Capital Markets Is Lowering PTC Therapeutics Inc. (PTCT) Q1 18 Estimate To -0.34 From -0.33
1/29/2018 6:48:10 AM
RBC Capital Markets Is Raising PTC Therapeutics Inc. (PTCT) FY18 Rev. Estimate To 275.9 M From 249.3 M
1/29/2018 6:47:57 AM
RBC Capital Markets Is Raising PTC Therapeutics Inc. (PTCT) FY17 Rev. Estimate To 193.5 M From 182.0 M